Drug
Edp 938
Edp 938: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 9 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-938 NCT05568706 | Phase 2 | RSV Infection |
| EDP-938 NCT04196101 | Phase 2 | Respiratory Syncytial Virus |
| EDP-938 NCT04633187 | Phase 2 | Respiratory Syncytial Virus Infections |
| EDP-938 NCT04816721 | Phase 2 | Respiratory Syncytial Virus (RSV) |
| EDP-938 NCT04871724 | Phase 1 | RSV Infection |
| EDP-938 NCT04498741 | Phase 1 | RSV Infection |
| EDP-938 NCT03384823 | Phase 1 | RSV Infection |
| EDP-938 NCT03750383 | Phase 1 | RSV Infection |
| EDP-938 NCT04927793 | Phase 1 | Respiratory Syncytial Virus (RSV) |
Latest
No recent events.
Follow Edp 938 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.